Methylation status of IGFBP-3 as a useful clinical tool for deciding on a concomitant radiotherapy

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi.org/10.3322/caac.20107
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-8; PMID:11784875; http://dx.doi.org/10.1056/NEJMoa011954
   PubMed Web of Science ®Google Scholar
• Yoshida EJ, Chen H, Torres MA, Curran WJ, Liu T. Spectrophotometer and ultrasound evaluation of late toxicity following breast-cancer radiotherapy. Med Phys 2011; 38:5747-55; PMID:21992389; http://dx.doi.org/10.1118/1.3633942
   PubMed Web of Science ®Google Scholar
• Cortes-Sempere M, de Miguel MP, Pernia O, Rodriguez C, de Castro Carpeno J, Nistal M, Conde E, Lopez-Rios F, Belda-Iniesta C, Perona R, et al. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIRAkt pathway in non-small cell lung cancer. Oncogene 2013; 32:1274-83; PMID:22543588; http://dx.doi.org/10.1038/onc.2012.146
   PubMed Web of Science ®Google Scholar
• Ibanez de Caceres I, Cortes-Sempere M, Moratilla C, Machado-Pinilla R, Rodriguez-Fanjul V, Manguan-Garcia C, Cejas P, Lopez-Rios F, Paz-Ares L, de CastroCarpeno J, et al. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. Oncogene 2010; 29:1681-90; PMID:20023704; http://dx.doi.org/10.1038/onc.2009.454
   PubMed Web of Science ®Google Scholar
• Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343:1350-4; PMID:11070098; http://dx.doi.org/10.1056/NEJM200011093431901
   PubMed Web of Science ®Google Scholar
• Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 2012; 13:679-92; PMID:22945394; http://dx.doi.org/10.1038/nrg3270
   PubMed Web of Science ®Google Scholar
• Roossink F, de Jong S, Wisman GB, van der Zee AG, Schuuring E. DNA hypermethylation biomarkers to predict response to cisplatin treatment, radiotherapy or chemoradiation: the present state of art. Cell Oncol (Dordr) 2012; 35:231-41; PMID:22836879; http://dx.doi.org/10.1007/s13402-012-0091-7
   PubMed Web of Science ®Google Scholar
• Isohashi F, Endo H, Mukai M, Inoue T, Inoue M. Insulin-like growth factor stimulation increases radiosensitivity of a pancreatic cancer cell line through endoplasmic reticulum stress under hypoxic conditions. Cancer Sci 2008; 99:2395-401; PMID:19018773; http://dx.doi.org/10.1111/j.1349-7006.2008.00970.x
   PubMed Web of Science ®Google Scholar
• Zhao L, He L, Xi M, Cai M, Shen J, Li Q, Liao Y, Qian D, Feng Z, Zeng Y, et al. Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3. J Transl Med 2012; 10:249; PMID:23232108; http://dx.doi.org/10.1186/1479-5876-10-249
   PubMed Web of Science ®Google Scholar
• Yoshino K, Motoyama S, Koyota S, Shibuya K, Usami S, Maruyama K, Saito H, Minamiya Y, Sugiyama T, Ogawa J. IGFBP3 and BAG1 enhance radiation-induced apoptosis in squamous esophageal cancer cells. Biochem Biophys Res Commun 2011; 404:1070-5; PMID:21195059; http://dx.doi.org/10.1016/j.bbrc.2010.12.115
   PubMed Web of Science ®Google Scholar
• Antwih DA, Gabbara KM, Lancaster WD, Ruden DM, Zielske SP. Radiation-induced epigenetic DNA methylation modification of radiation-response pathways. Epigenetics 2013; 8:839-48; PMID:23880508; http://dx.doi.org/10.4161/epi.25498
   PubMed Web of Science ®Google Scholar
• Skvortsova I, Skvortsov S, Stasyk T, Raju U, Popper BA, Schiestl B, von Guggenberg E, Neher A, Bonn GK, Huber LA, et al. Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics 2008; 8:4521-33; PMID:18821526; http://dx.doi.org/10.1002/pmic.200800113
   PubMed Web of Science ®Google Scholar
• Sanchez-Perez I, Murguia JR, Perona R. Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 1998; 16:533-40; PMID:9484843; http://dx.doi.org/10.1038/sj.onc.1201578
   PubMedGoogle Scholar
• Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, Van Criekinge W, Westra WH, Schoenberg M, Zahurak M, Goodman SN, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 2006; 98:996-1004; PMID: 16849682; http://dx.doi.org/10.1093/jnci/djj265
   PubMed Web of Science ®Google Scholar
• Ibanez de Caceres I, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG, Cairns P. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res 2006; 66:5021-8; PMID:16707423; http://dx.doi.org/10.1158/0008-5472.CAN-05-3365
   PubMed Web of Science ®Google Scholar
• Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, Shen R, Gunderson KL. Genome-wide DNA methylation profiling using Infinium(R) assay. Epigenomics 2009; 1:177-200; PMID:22122642; http://dx.doi.org/10.2217/epi.09.14
   PubMed Web of Science ®Google Scholar
• Ibragimova I, Maradeo M, Dulaimi E, Cairns P. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC. Epigenetics 2013; 8:486-93; PMID:23644518; http://dx.doi.org/10.4161/epi.24552
   PubMed Web of Science ®Google Scholar
• De Schutter H, Geeraerts H, Verbeken E, Nuyts S. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only. Oncol Rep 2009; 21:507-13; PMID:19148529
   PubMed Web of Science ®Google Scholar
• Niyazi M, Schnell O, Suchorska B, Schwarz SB, Ganswindt U, Geisler J, Bartenstein P, Kreth FW, Tonn JC, Eigenbrod S, et al. FET-PET assessed recurrence pattern after radio-chemotherapy in newly diagnosed patients with glioblastoma is influenced by MGMT methylation status. Radiother Oncol 2012; 104:78-82; PMID:22673727; http://dx.doi.org/10.1016/j.radonc.2012.04.022
   PubMed Web of Science ®Google Scholar
• Moeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev 2007; 26:241-8; PMID:17440683; http://dx.doi.org/10.1007/s10555-007-9056-0
   PubMed Web of Science ®Google Scholar
• Campos AC, Molognoni F, Melo FH, Galdieri LC, Carneiro CR, D’Almeida V, Correa M, Jasiulionis MG. Oxidative stress modulates DNA methylation during melanocyte anchorage blockade associated with malignant transformation. Neoplasia 2007; 9:1111-21; PMID:18084618; http://dx.doi.org/10.1593/neo.07712
   PubMed Web of Science ®Google Scholar
• Chan CL, Wu Z, Eastman A, Bresnick E. Irradiation-induced expression of O6-methylguanine-DNA methyltransferase in mammalian cells. Cancer Res 1992; 52:1804-9; PMID:1372530
   PubMed Web of Science ®Google Scholar
• Raiche J, Rodriguez-Juarez R, Pogribny I, Kovalchuk O. Sex- and tissue-specific expression of maintenance and de novo DNA methyltransferases upon low dose X-irradiation in mice. Biochem Biophys Res Commun 2004; 325:39-47; PMID:15522198; http://dx.doi.org/10.1016/j.bbrc.2004.10.002
   PubMed Web of Science ®Google Scholar
• Carter S, Auer KL, Reardon DB, Birrer M, Fisher PB, Valerie K, Schmidt-Ullrich R, Mikkelsen R, Dent P. Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells. Oncogene 1998; 16:2787-96; PMID:9652746; http://dx.doi.org/10.1038/sj.onc.1201802
   PubMed Web of Science ®Google Scholar
• Hagan M, Wang L, Hanley JR, Park JS, Dent P. Ionizing radiation-induced mitogen-activated protein (MAP) kinase activation in DU145 prostate carcinoma cells: MAP kinase inhibition enhances radiation-induced cell killing and G2M-phase arrest. Radiat Res 2000; 153:371-83; PMID:10760996; http://dx.doi.org/10.1667/0033-7587(2000)153%5b0371:IRIMAP%5d2.0.CO;2
   PubMed Web of Science ®Google Scholar
• Valerie K, Yacoub A, Hagan MP, Curiel DT, Fisher PB, Grant S, Dent P. Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther 2007; 6:789-801; PMID:17363476; http://dx.doi.org/10.1158/1535-7163.MCT-06-0596
   PubMed Web of Science ®Google Scholar
• Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S. MAPK pathways in radiation responses. Oncogene 2003; 22:5885-96; PMID:12947395; http://dx.doi.org/10.1038/sj.onc.1206701
   PubMed Web of Science ®Google Scholar
• Che J, Lu YW, Sun KK, Feng C, Dong AJ, Jiao Y. Overexpression of TOB1 confers radioprotection to bronchial epithelial cells through the MAPKERK pathway. Oncol Rep 2013; 30:637-42; PMID:23756562
   PubMed Web of Science ®Google Scholar
• Shannon AM, Telfer BA, Smith PD, Babur M, Logie A, Wilkinson RW, Debray C, Stratford IJ, Williams KJ, Wedge SR. The mitogen-activated proteinextracellular signal-regulated kinase kinase 12 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts. Clin Cancer Res 2009; 15:6619-29; PMID:19843666; http://dx.doi.org/10.1158/1078-0432.CCR-08-2958
   PubMed Web of Science ®Google Scholar
• Grant S, Qiao L, Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci 2002; 7:d376-89; PMID:11815285; http://dx.doi.org/10.2741/grant
   PubMed Web of Science ®Google Scholar
• Qiao L, Yacoub A, McKinstry R, Park JS, Caron R, Fisher PB, Hagan MP, Grant S, Dent P. Pharmocologic inhibitors of the mitogen activated protein kinase cascade have the potential to interact with ionizing radiation exposure to induce cell death in carcinoma cells by multiple mechanisms. Cancer Biol Ther 2002; 1:168-76; PMID:12170777; http://dx.doi.org/10.4161/cbt.64
   PubMed Web of Science ®Google Scholar
• Su WH, Chuang PC, Huang EY, Yang KD. Radiation-induced increase in cell migration and metastatic potential of cervical cancer cells operates via the K-Ras pathway. Am J Pathol 2012; 180:862-71; PMID:22138581; http://dx.doi.org/10.1016/j.ajpath.2011.10.018
   PubMed Web of Science ®Google Scholar
• Smits KM, Melotte V, Niessen HE, Dubois L, Oberije C, Troost EG, Starmans MH, Boutros PC, Vooijs M, van Engeland M, et al. Epigenetics in radiotherapy: Where are we heading? Radiother Oncol 2014; 111:168-77; PMID:24861629; http://dx.doi.org/10.1016/j.radonc.2014.05.001
   PubMed Web of Science ®Google Scholar